Floatz logo

Mirvetuximab Soravtansine

BRCA1 Gene Mutation

Ohio State University Comprehensive Cancer Centerantibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the BRCA1 Gene Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
M.D. Anderson Cancer Center
Phase 2BB
Niraparib
Qian Qin
Phase 3B
Veliparib
Steven J Isakoff, MD, PhD
Phase 2B
Durvalumab
Roswell Park Cancer Institute
Phase 2B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Roswell Park Cancer Institute
Phase 2B

View all 16 →

Same molecule, other indications

Mirvetuximab Soravtansine is also rated in:

ovarian carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
fallopian tube cancerDormant
BB
Indicative ·
70 / 100
View asset →
primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →